179 related articles for article (PubMed ID: 16550160)
1. Polymorphisms in the p53 pathway.
Pietsch EC; Humbey O; Murphy ME
Oncogene; 2006 Mar; 25(11):1602-11. PubMed ID: 16550160
[TBL] [Abstract][Full Text] [Related]
2. Association of p53 polymorphisms with breast cancer: a case-control study in Slovak population.
Franeková M; Zúbor P; Stanclová A; Dussan CA; Bohusová T; Galo S; Dobrota D; Kajo K; Péc M; Racay P
Neoplasma; 2007; 54(2):155-61. PubMed ID: 17319790
[TBL] [Abstract][Full Text] [Related]
3. A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression.
De Feo E; Persiani R; La Greca A; Amore R; Arzani D; Rausei S; D'Ugo D; Magistrelli P; van Duijn CM; Ricciardi G; Boccia S
Mutat Res; 2009 Apr; 675(1-2):60-5. PubMed ID: 19386249
[TBL] [Abstract][Full Text] [Related]
4. [p53 as a molecular target for cancer therapy].
Ishioka C; Osada M; Gamo M; Kanamaru R
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2207-12. PubMed ID: 9422063
[TBL] [Abstract][Full Text] [Related]
5. The genetics of the p53 pathway, apoptosis and cancer therapy.
Vazquez A; Bond EE; Levine AJ; Bond GL
Nat Rev Drug Discov; 2008 Dec; 7(12):979-87. PubMed ID: 19043449
[TBL] [Abstract][Full Text] [Related]
6. GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer.
Csejtei A; Tibold A; Varga Z; Koltai K; Ember A; Orsos Z; Feher G; Horvath OP; Ember I; Kiss I
Anticancer Res; 2008; 28(3B):1917-22. PubMed ID: 18630481
[TBL] [Abstract][Full Text] [Related]
7. The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases.
De Vecchi G; Verderio P; Pizzamiglio S; Manoukian S; Bernard L; Pensotti V; Volorio S; Ravagnani F; Radice P; Peterlongo P
Cancer Detect Prev; 2008; 32(2):140-3. PubMed ID: 18640791
[TBL] [Abstract][Full Text] [Related]
8. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer.
Ku TK; Nguyen DC; Karaman M; Gill P; Hacia JG; Crowe DL
Mol Cancer Res; 2007 Apr; 5(4):351-62. PubMed ID: 17426250
[TBL] [Abstract][Full Text] [Related]
9. Mouse models with modified p53 sequences to study cancer and ageing.
Clarke AR; Hollstein M
Cell Death Differ; 2003 Apr; 10(4):443-50. PubMed ID: 12719721
[TBL] [Abstract][Full Text] [Related]
10. p53 Arg72Pro polymorphism predicts survival outcome in lung cancer patients in Indian population.
Sreeja L; Syamala V; Raveendran PB; Santhi S; Madhavan J; Ankathil R
Cancer Invest; 2008 Feb; 26(1):41-6. PubMed ID: 18181044
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction?
Tan XL; Nieters A; Hoffmeister M; Beckmann L; Brenner H; Chang-Claude J
Pharmacogenet Genomics; 2007 Aug; 17(8):639-45. PubMed ID: 17622940
[TBL] [Abstract][Full Text] [Related]
12. Exploiting the p53 pathway for the diagnosis and therapy of human cancer.
Lane DP
Cold Spring Harb Symp Quant Biol; 2005; 70():489-97. PubMed ID: 16869788
[TBL] [Abstract][Full Text] [Related]
13. Recent natural selection identifies a genetic variant in a regulatory subunit of protein phosphatase 2A that associates with altered cancer risk and survival.
Grochola LF; Vazquez A; Bond EE; Würl P; Taubert H; Müller TH; Levine AJ; Bond GL
Clin Cancer Res; 2009 Oct; 15(19):6301-8. PubMed ID: 19773383
[TBL] [Abstract][Full Text] [Related]
14. Association of p53 and p21(CDKN1A/WAF1/CIP1) polymorphisms with oral cancer in Taiwan patients.
Bau DT; Tsai MH; Lo YL; Hsu CM; Tsai Y; Lee CC; Tsai FJ
Anticancer Res; 2007; 27(3B):1559-64. PubMed ID: 17595776
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
Zhang AL; Russell PJ; Knittel T; Milross C
Prostate; 2007 Nov; 67(15):1630-40. PubMed ID: 17823933
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
Selivanova G; Wiman KG
Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
[TBL] [Abstract][Full Text] [Related]
17. Association of p53 polymorphisms and colorectal cancer: modulation of risk and progression.
Mammano E; Belluco C; Bonafé M; Olivieri F; Mugianesi E; Barbi C; Mishto M; Cosci M; Franceschi C; Lise M; Nitti D
Eur J Surg Oncol; 2009 Apr; 35(4):415-9. PubMed ID: 18468835
[TBL] [Abstract][Full Text] [Related]
18. The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death.
Chari NS; Pinaire NL; Thorpe L; Medeiros LJ; Routbort MJ; McDonnell TJ
Apoptosis; 2009 Apr; 14(4):336-47. PubMed ID: 19229632
[TBL] [Abstract][Full Text] [Related]
19. Generation and characterization of p53 mutant mice.
Dumble ML; Donehower LA; Lu X
Methods Mol Biol; 2003; 234():29-49. PubMed ID: 12824523
[TBL] [Abstract][Full Text] [Related]
20. p53 genotypes and haplotypes associated with risk of breast cancer.
Buyru N; Altinisik J; Demokan S; Dalay N
Cancer Detect Prev; 2007; 31(3):207-13. PubMed ID: 17574348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
